Across TCGA pan-cancer cohorts, LINC00428 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC00428’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC00428 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00428 is over-expressed in tumor.
PRAD are the cancer types where LINC00428 tumor–normal differential expression is most reproducible.